The French laboratory Sanofi published rising results in 2022 on Friday, still boosted by its drug Dupixent, and anticipates a year 2023 in growth, but at a more moderate level.
Net profit increased by 8% to 6.72 billion euros. Net profit from activities, the indicator favored by the group, which excludes exceptional effects, rose by almost 26%, to 10.34 billion euros.
Net earnings per share from activities (EPS), another key indicator for the laboratory, also rose to 8.26 euros (+17.1% at constant exchange rates), above Sanofi’s objectives.
For 2023, Sanofi nevertheless anticipates a slowdown in the growth of this indicator, “in the low single-digit range” at constant exchange rates, he said in his press release.
Last year, the company, which employs 100,000 people worldwide, recorded sales of 42.3 billion euros (+13.9%, +7% CER). However, this is less than anticipated by analysts polled by Bloomberg.
Sanofi announced that it would propose the payment of a dividend of 3.56 euros, once morest 3.33 euros per share for the previous financial year. Which would amount, according to AFP estimates, to a total payment of more than 4.4 billion euros to its shareholders.
In detail, the specialty medicine division, the flagship of Sanofi, now dominates the group’s sales, at 16.46 billion euros (+ 19.4% CER).
Within this division, the blockbuster Dupixent remains the main driver: this drug, developed jointly by the French laboratory and its American partner Regeneron, has already been launched for several pathologies in around thirty countries, including asthma and eczema. .
Dupixent reported nearly 8.3 billion euros in sales for the year.
